文献速递甲状腺疾病

分化型甲状腺癌大结节性肺转移的生长动力学与生存

Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2017-05-25

本研究纳入44例分化型甲状腺癌大结节性肺转移(≥1 cm)患者,通过系列胸部CT按RECIST评估肺转移生长动力学。按进展时间分为慢速(≥3年,15例,34%)、中速(1-3年,17例,39%)和快速(<1年,12例,27%)三组,三组生长均呈线性模式。快速组肿瘤负荷倍增时间为1.8年(R²=0.973,p=0.013),中速组和慢速组估计倍增时间分别为5.9年和19.3年。多因素分析显示首年内疾病进展是癌症特异性生存(CSS)的独立预测因素(风险比=8.6;p=0.003)。

要点

  • 44例DTC大结节性肺转移患者按进展时间分为慢速(≥3年,34%)、中速(1-3年,39%)、快速(<1年,27%)三组。
  • 快速组肿瘤负荷倍增时间为1.8年(R²=0.973,p=0.013),中速组和慢速组估计分别为5.9年和19.3年。
  • 首年内疾病进展是CSS的独立预测因素(风险比=8.6;p=0.003)。

核心结论

  • 首年内肿瘤生长动力学是大结节性肺转移患者CSS的独立预测因素。

研究设计与样本

  • 纳入44例分化型甲状腺癌大结节性肺转移(≥1 cm)患者,采用系列胸部CT按RECIST评估生长动力学并比较CSS。

主要发现

  • 按进展时间分为慢速(≥3年)15例(34%)、中速(1-3年)17例(39%)、快速(<1年)12例(27%)。
  • 三组肺转移生长动力学均呈线性模式。
  • 快速组肿瘤负荷倍增时间为1.8年(R²=0.973,p=0.013),中速组和慢速组估计倍增时间分别为5.9年和19.3年。
  • 无独立变量可预测肺转移的生长动力学。
  • 多因素分析中,首年内疾病进展是CSS的独立预测因素(风险比=8.6;p=0.003)。

临床怎么用

  • 作者认为,在大结节性肺转移患者疾病早期每年至少进行两次胸部CT检查可能有助于识别适合酪氨酸激酶抑制剂治疗的高风险患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical course of patients with lung metastases of differentiated thyroid carcinoma (DTC) vary, and cancer-specific survival (CSS) can be associated with tumor burden. This study evaluated the growth kinetics of lung metastases from DTC using serial chest computed tomography for Response Evaluation Criteria in Solid Tumors assessment and its prognostic implications. METHODS: Forty-four patients with macronodular lung metastases (≥1 cm) of DTC were included. The time intervals to disease progression of lung metastases were measured and compared to CSS rates. RESULTS: On the basis of the time to progression, 15 (34%), 17 (39%), and 12 (27%) patients were classified into the slow (≥3 years), moderate (1-3 years), and rapid groups (<1 year), respectively. The growth kinetics of lung metastases exhibited a linear pattern in the three groups. The doubling time of tumor burden was 1.8 years (R2 = 0.973, p = 0.013) in the rapid group, and the estimated doubling time of the tumor burden in the moderate and slow groups was 5.9 years and 19.3 years, respectively. No independent variable predicted the growth kinetics of lung metastases. In multivariate analysis, disease progression within the first year was an independent predictor of CSS (hazard ratio = 8.6; p = 0.003). CONCLUSIONS: This is the first study to demonstrate objectively that tumor growth kinetics within the first year are an independent predictor of CSS in patients with macronodular lung metastases. Performing chest computed tomography at least twice a year in the early phase of the disease in patients with macronodular lung metastases may be helpful for identifying high-risk patients who are eligible for treatment with tyrosine kinase inhibitors.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kim M, Kim WG, Park S, et al. Growth Kinetics of Macronodular Lung Metastases and Survival in Differentiated Thyroid Carcinoma. Thyroid. 2017. PMID: 28463599. doi:10.1089/thy.2016.0676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。